CLBT CLBT
Company Profile ↓Company Overview
CLBT (CLBT) is a publicly traded company listed on with a market capitalization of $3.89B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 16.2%, reflecting efficient use of shareholder capital.
Revenue has grown at a 20.7% CAGR over the past five years.
Maintains a net profit margin of 16.5%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $475.68M (+18.6% YoY); net profit $78.33M.
- Trailing 12 Months Year-on-year growth — revenue +18.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 20.7%, profit CAGR -13.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 20.68% |
| 1 Year: | 18.56% |
Compounded Profit Growth
| 5 Years: | -13.45% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +14.66% |
| 6 Months: | +9.52% |
| 3 Months: | +15.08% |
| 1 Month: | -5.61% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)58.52 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 20.7% over 5 years.
- Generates positive free cash flow.
CONS
- Trading at a high P/E of 50.5.
- Earnings shrank at -13.5% CAGR over 5 years.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 107.55M | 113.28M | 126.03M | 128.82M | 128.30M |
| Cost of Revenue | 17.49M | 17.68M | 20.31M | 19.69M | 22.42M |
| Gross Profit | 90.06M | 95.60M | 105.72M | 109.13M | 105.88M |
| Operating Expenses | 77.79M | 81.18M | 86.72M | 88.33M | 96.76M |
| Operating Income | 12.27M | 14.42M | 18.99M | 20.80M | 9.12M |
| EBITDA | 14.90M | 30.52M | 21.69M | 49.47M | 16.12M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | 19.33M | 20.79M | 24.29M | 26.27M | 13.63M |
| Tax Provision | 1.93M | 1.31M | 4.10M | 5.01M | 2.70M |
| Net Income | 17.40M | 19.48M | 20.19M | 21.26M | 10.94M |
| Diluted EPS | 0.07 | 0.08 | 0.08 | 0.08 | 0.04 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 270.65M | 325.11M | 401.20M | 475.68M |
| Cost of Revenue | - | 50.75M | 53.23M | 62.59M | 75.17M |
| Gross Profit | - | 219.91M | 271.88M | 338.61M | 400.50M |
| Operating Expenses | - | 218.86M | 238.64M | 281.70M | 334.02M |
| Operating Income | - | 1.04M | 33.24M | 56.91M | 66.48M |
| EBITDA | - | 130.10M | -65.41M | -265.35M | 103.07M |
| Interest Expense | - | 149.00K | 141.00K | 29.00K | 523.00K |
| Pretax Income | - | 120.76M | -75.56M | -275.98M | 90.68M |
| Tax Provision | - | -45.00K | 5.54M | 7.02M | 12.35M |
| Net Income | - | 120.81M | -81.10M | -283.01M | 78.33M |
| Diluted EPS | - | 0.59 | -0.43 | -1.35 | 0.31 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 403.29M | 532.88M | 690.57M | 938.85M |
| Current Assets | - | 295.93M | 422.08M | 567.59M | 575.85M |
| Cash & Equivalents | - | 87.64M | 189.52M | 191.66M | 124.46M |
| Inventory | - | 10.18M | 9.94M | 8.94M | 7.60M |
| Receivables | - | 78.76M | 77.27M | 82.36M | 104.97M |
| Total Liabilities | - | 329.43M | 498.67M | 354.55M | 454.53M |
| Current Liabilities | - | 207.78M | 253.82M | 295.50M | 369.66M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 15.36M | 14.13M | 10.97M | 22.67M |
| Total Equity | - | 73.86M | 34.21M | 336.02M | 484.32M |
| Shares Outstanding | - | 193.06M | 203.27M | 234.57M | 248.62M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 20.58M | 102.06M | 132.17M | 173.54M |
| Investing Cash Flow | - | -91.23M | -22.54M | -149.47M | -268.25M |
| Financing Cash Flow | - | 13.97M | 21.77M | 20.65M | 25.05M |
| Capital Expenditure | - | -9.09M | -7.92M | -10.61M | -13.22M |
| Free Cash Flow | - | 11.49M | 94.14M | 121.56M | 160.32M |
| Net Change in Cash | - | -56.68M | 101.28M | 3.35M | -69.65M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 81.3% | 83.6% | 84.4% | 84.2% |
| Operating Margin % | - | 0.4% | 10.2% | 14.2% | 14.0% |
| Net Margin % | - | 44.6% | -24.9% | -70.5% | 16.5% |
| ROE % | - | 163.5% | -237.1% | -84.2% | 16.2% |
| ROCE % | - | 0.5% | 11.9% | 14.4% | 11.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CLBT
Cellebrite Q1 2026 Beat Fuels 99% Upside Case for CLBT Stock - TIKR.com
<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxQcTNMQUxMZFRwSEx6dmlmdm1nUFdkZGRMcVYwek52bmlLSkNKTlRsdHQySUQ5WXQyQnBSYXVQYXQ2b0ZSLWtXbHpGT1BmYzBYXzhNdUZrbDBadjByMDZ4YTJXejRRLVBJeHFVZW01X3VObnFqOW9qX19BbTliNGlXVWY5NExyRlUxMncxQ0…
Is Cellebrite DI Ltd. (CLBT) A Good Stock To Buy Now? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxOMVlfUkptSmNhWndqeVlVaW5UUVAycTZCWHRnZ2VHeGZxbjRaV29Zb1VyVUtpMTRSVG1yQnZnYlRQRmp3QVJ0NTZkVmUtY0ZhT3VKWklocHBObW04eWpZSGtJemNuUVhERHJSdTMyR3VtRDJIVHhYNGxxUndpLXpSWUJhVDBkNGtham9Md2…
Lazard Asset Management LLC Makes New Investment in Cellebrite DI Ltd. $CLBT - MarketBeat
<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxPYnNUclZETVB3ZHdVeG5FdHl1R3Zid2ViNk5oa2RlYVJFc3NwcnBYUGtLM08yTFpBMlBpeDNZZWkzMmZVc3c5RGRaemk0NDRnZFhTTzEwaEsxSUhyelgyY3ppNVZUZVZyd0Qzb3JiTjdNWnVPbVRGSE1jUW10cEMyMzBmT2NyR05jQlJ6NF…
UKGI Data Breach Puts Cellebrite Stock And Cybersecurity Shares In Focus - simplywall.st
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxPcTRqaDBxQkxGN1NUVGdzZTA1NkJyQm9JN3NHMEFvZVFNWFV5MVFIbW5UN29nS1RIaE9CeUpjZENRWVptSHdjQUhBM1BHZzNLLXdwSmtCcUt1X1pxOGJ3UWpndGlhSFp0WUdYaktxdEFzVlBlZlZHeG5ObVVEUHJ0RHZPZGFmbDhCaW9xY1…
$CLBT stock is up 10% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQUEwxX0NjMzBieThHeDVvSEdueDBvRzJBWjNVNlRlZFkzWDE2WHJ5NDR4aVZzUWtlaWZZckRuSGl4Y1Jta0U4UjFuR3ZvdmNPa1RMYzBvQXVhczVOR0RWMHU4R0ZyT21ieXRaVTNHZVFJQlN0ejdPNnhxbHpsWVdJTTdyTU5ob21uVmRFU3…
Cellebrite: Stronger Fundamentals Support A Buy Rating (NASDAQ:CLBT) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNaE9QZEQ3dWNTdWt2OFVOU29MYUwtYkRMZjgyR3dSeVRpdVRVV0tGNGNIVjhKTVFpNFc4a096WnRsa2R2RlFjYWtVRkRzMi1UU0p2ZHVCVkZscndWVGl5V2FZYk1DWG1Xbkp1ZmZYQVdWNDNSSnRUS2l0Uy1BRnlIa0pXaXpmOWJFUmg3RW…
CLBT — Frequently Asked Questions
What is the current share price of CLBT?
As of 2026-08-05 17:25 PDT, CLBT trades at $15.64 on NASDAQ/NYSE. Its 52-week range is $11.03 to $19.56.
What is the market capitalisation of CLBT?
CLBT has a market capitalisation of $3.89B on NASDAQ/NYSE.
What is the P/E ratio of CLBT?
CLBT trades at a trailing price-to-earnings (P/E) ratio of 50.45. Its price-to-book (P/B) ratio is 8.03.
What is the return on equity (ROE) of CLBT?
CLBT has a return on equity (ROE) of 16.17%. Its return on capital employed (ROCE) is 11.68%.
Is CLBT a good stock to buy?
This page provides a data-driven analysis of CLBT, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.